Skip to content
Synopulse
  • The Brief
    • Quick
    • In Depth
    • Editor’s Pick
    • Findings
  • Reports
    • The beats
      • Catalyst
      • AccessWatch
      • DealPulse Signal
      • DealPulse Report
    • Analysis
      • The Throughline
      • The Top Line
      • The Forecast
    • Coverage
      • ShowFloor
      • The Arena
  • The Pulse
    • NeuroPulse
    • OrphanPulse
  • Topics
    • By subject
      • Deals
      • Regulatory
      • Market Access
      • Pricing & Reimbursement
      • Legal & Policy
    • By technology
      • Antibody
      • Cell & Gene Tx
      • Drug conjugates
      • AI/ML
      • Digital Health
      • Radiopharma
    • By therapy area
      • Neurology
      • Oncology
      • Rare Diseases
      • Cardio-Metabolic
      • Immunology & Inflammation
      • Orthopaedics
This Money Buys Equipment, Not Operations. Your 2031 Answer Decides the 2027 Deal.
This Money Buys Equipment, Not Operations. Your 2031 Answer Decides the 2027 Deal.
Athithi Verma August 27, 2026
Half the pot is split equally, so award size is a weak proxy for market size. Your buyer is a state rural health office, not…
Three Proteins Flip the Tumour Sphere. Blocking Two of Them Flips It Back Toward Chemo-Resistance.
Three Proteins Flip the Tumour Sphere. Blocking Two of Them Flips It Back Toward Chemo-Resistance.
Evernorth Adopts LOCUS in Three States, and States That the Review Process Is Not Changing
Evernorth Adopts LOCUS in Three States, and States That the Review Process Is Not Changing
A Jury Convicted the Philips Engineer. The Approach Came as His Plant Was Closing.
A Jury Convicted the Philips Engineer. The Approach Came as His Plant Was Closing.
DOJ Settled With the In-Home Vendor, Not the Health Plan, Over Four Medicare Advantage Codes
DOJ Settled With the In-Home Vendor, Not the Health Plan, Over Four Medicare Advantage Codes
Teva Faces New Probe in Turkey Over Conduct Flagged by EU
Teva Faces New Probe in Turkey Over Conduct Flagged by EU

Editor’s Pick

In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part

In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part

In Japan, Expanding a Label Is What Triggers the Price Cut

In Japan, Expanding a Label Is What Triggers the Price Cut

AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.

AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.

NeuroPulse


NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard

NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard

NeuroPulse Wk 32: Takeda Fixed the Cause, and Cannot Ship It Yet

NeuroPulse Wk 32: Takeda Fixed the Cause, and Cannot Ship It Yet

OrphanPulse


OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later

OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later

OrphanPulse Wk 32: Tarsus Paid $450M Upfront for a Readout in 2029

OrphanPulse Wk 32: Tarsus Paid $450M Upfront for a Readout in 2029

DealPulse Signal


DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Report


DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealFlow H1 2026 M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

The Beats


DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

Analysis


Reshaping Pharma by 2027

7 Market Access Trends Reshaping Pharmaย by 2027

The Biologics Patent Cliff: Inside Pharma's 2026-2029 Reckoning

The Biologics Patent Cliff: Inside Pharma’s 2026-2029 Reckoning

Coverage


The ADC Decade Accelerates What to Watch at ASCO 2026

The ADC Decade Accelerates: What to Watch at ASCO 2026

The Briefs

This Money Buys Equipment, Not Operations. Your 2031 Answer Decides the 2027 Deal.

This Money Buys Equipment, Not Operations. Your 2031 Answer Decides the 2027 Deal.

Athithi Verma August 27, 2026
Three Proteins Flip the Tumour Sphere. Blocking Two of Them Flips It Back Toward Chemo-Resistance.

Three Proteins Flip the Tumour Sphere. Blocking Two of Them Flips It Back Toward Chemo-Resistance.

Athithi Verma August 27, 2026
Evernorth Adopts LOCUS in Three States, and States That the Review Process Is Not Changing

Evernorth Adopts LOCUS in Three States, and States That the Review Process Is Not Changing

Athithi Verma August 27, 2026
A Jury Convicted the Philips Engineer. The Approach Came as His Plant Was Closing.

A Jury Convicted the Philips Engineer. The Approach Came as His Plant Was Closing.

Athithi Verma August 27, 2026
DOJ Settled With the In-Home Vendor, Not the Health Plan, Over Four Medicare Advantage Codes

DOJ Settled With the In-Home Vendor, Not the Health Plan, Over Four Medicare Advantage Codes

Athithi Verma August 27, 2026
Teva Faces New Probe in Turkey Over Conduct Flagged by EU

Teva Faces New Probe in Turkey Over Conduct Flagged by EU

Athithi Verma August 27, 2026
Read More
Synopulse
Contact Us

Explore Synopulse

  • NeuroPulse
  • Deals
  • Market Access
  • Industry Trends
  • Regulatory

About

  • About Synopulse
  • Contact Us
  • Announcements
© 2026 Synopulse • Built with GeneratePress